Tag: #biotech-ai10 results
Google is set to unveil the Gemini 3.5 model and Jinju XR glasses at the upcoming I/O conference. Meanwhile, Nvidia is expanding its hardware footprint with the delivery of Vera CPUs to major AI labs, signaling a shift toward full-stack AI infrastructure.
Aureka Biotechnologies completed a $35M Series A+ funding round led by Sequoia China to advance its AuraIDE™ AI platform for antibody design. Funds will boost base models, intelligent agents, and high-throughput experimental infrastructure. The company's first AI-designed antibody drug nears clinical trials.
OpenAI is rolling out an early version of an AI model designed to accelerate drug discovery. This move positions OpenAI to compete with Google in leveraging AI for scientific breakthroughs. Tech companies are increasingly targeting this space for innovation.
Anthropic acquired stealth biotech AI startup Coefficient Bio in an all-stock deal valued at over $400 million. The startup, founded just eight months ago, has fewer than 10 employees, mostly former Genentech computational biology researchers. The team joins Anthropic's healthcare and life sciences division.
Roche is using Recursion’s AI capabilities to identify new targets for brain diseases. The effort reflects a broader push to use AI to reduce failures in drug development.
Generative AI-driven biotech firm Insilico Medicine has piloted Automated Partnering System. The platform automates initial due diligence inquiries using a pre-loaded database. It upgrades manual communication into fully automated closed-loop processes.
AstraZeneca is in preliminary talks with Bristol Myers Squibb regarding a potential merger. If successful, this deal would create a $400 billion pharmaceutical giant, marking a record-breaking consolidation in the industry.
China ranked third in the new Global AI Competitiveness Index for biotechnology, healthcare, and longevity. The index, released by Deep Knowledge Group, places it behind only the US and UK. It highlights AI's shift to regulated sectors like drug discovery and diagnostics.
Eight mainland China companies, including five biotech firms, passed Hong Kong listing hearings in April to access deep liquidity. Highlights include an AI-driven drug discovery firm, driverless tech developer, and industrial robot maker. This follows CSRC's push for private firms to list in Hong Kong.
AI pharmaceutical technology reaches singularity and industry turning point. An acceleration key has been pressed, signaling rapid progress in drug discovery.